



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/008,356	11/13/2001	Kenneth H. Falchuk	10498-00028	5003

22910 7590 12/16/2003
BANNER & WITCOFF, LTD.
28 STATE STREET
28th FLOOR
BOSTON, MA 02109-9601

EXAMINER

HANLEY, SUSAN MARIE

ART UNIT	PAPER NUMBER
----------	--------------

1651

//

DATE MAILED: 12/16/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/008,356

Applicant(s)

FALCHUK, KENNETH H.

Examiner

Susan Hanley

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 September 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-43 is/are pending in the application.
- 4a) Of the above claim(s) 8,9,16,17,19-21,33,34 and 41-43 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7,10-15,18,22-25,27-32 and 35-40 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3, 5 and 9. 6) ☐ Other: _____

Election/Restrictions

Applicant's election without traverse of claims 1-7, 10-15, 18, 22-25, 27-32 and 35-40 in Paper No. 10 is acknowledged.

Claims 8, 9, 16, 17, 19-21, 26, 33, 34 and 41-43 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Priority

Applicant's claim for domestic priority is acknowledged.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1-7, 10-15 and 22-24 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-7, 10-15 and 20-24 of copending Application No. 09/977,886. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

Art Unit: 1651

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 18 is provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 10 of copending Application No. 09/977,866. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 18 of the instant application specifies that that at least one Y substituent in the structure of claim 10 is a carbonyl. Claim 10 of co-pending application 09/977,866 specifies that substituent Y represents a substituted or unsubstituted alkyl, alkenyl or alkynyl group. Copending application 09/977,866 (page 10, lines 1-3) disclose that a substituted alkyl group comprises a carbonyl group. Since a carbonyl group is within the scope of the definition of the Y substituent, it would have been obvious to select a carbonyl-substituted group for the Y substituent because such a limitation is within the scope of the definition of the Y substituent in copending application 09/977,866.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-7 and 27-32 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for inhibition of cell proliferation, does not reasonably provide enablement for promoting cell proliferation. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. Claims 1 and 27-32 are drawn to a method of modulating cell proliferation or cell differentiation. Claims 2-7 are drawn to a method of modulating or regulating cell proliferation. According to Webster's Dictionary, modulating is adapting or adjusting to a certain proportion (p. 762) and regulating is defined as adjusting to a requirement or specification (p. 990). Both words do not limit the direction of the adjustment. That is, they imply that the change in a system can increase or decrease a parameter. Given these definitions, the scope of the instant claims comprise addition of the claimed substance to cells to increase or decrease proliferation of said cells. Applicant shows only that the addition of the claimed bilins to a cell culture causes arrest of cell proliferation. The prior art also discloses that the addition of bilins such as biliverdin or bilirubin, effects a decrease in cell proliferation. For example, Janes *et al.* discloses that the addition of unconjugated bilirubin impairs the proliferation of human osteoblasts (Fig. 3, p. 2583). Likewise, Vssilopoulou-Sellin *et al.* report that bilirubin inhibited the

Art Unit: 1651

proliferation of avian chondrocytes in a dose-dependent fashion (Fig. 1, p. 770). The broadest reasonable interpretation of the terms regulating or modulating is the increasing or decreasing of an activity. The prior art does not suggest that bilins such as bilirubin cause an increase in proliferative activity. Applicant discloses only inhibition of cell proliferation. Hence, the degree of unpredictability is very high and one of ordinary skill in the art would not reasonably expect to achieve an increase in cell proliferation upon the addition of bilins to compositions comprising cells. Absent a further showing, the claims are enabled for the inhibition of cell proliferation.

Claims 3-4, 28-29 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for inhibiting cell proliferation wherein the concentration of the claimed compound is 10^{-7} M or greater, does not reasonably provide enablement for inhibition or cell proliferation at concentrations of 10^{-8} M or less. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. The claims are drawn to the regulation of cell proliferation or cell differentiation at concentrations of 1 mM or less and 1 μ M or less. However, the specification discloses only the inhibition of cell proliferation (*vide supra*) and that biliverdin has no effect on cell proliferation or survival at concentration less than 10^{-7} M (page 102). The prior art does not disclose that bilins inhibit cell proliferation at levels less than 1 μ M (see Janes *et al.*, Figure 3, p. 2583). Hence, Applicant specifically discloses that bilins do not inhibit cell proliferation at concentrations of 10^{-8} M or less.

Art Unit: 1651

The prior art also does not suggest such a phenomenon. Hence, the degree of unpredictability is very high and one of ordinary skill in the art would not reasonably expect to inhibit cell proliferation wherein the concentration of the claimed inhibitor is 10^{-8}M or less. Absent a further showing, the claims are enabled for the inhibition of cell proliferation at a concentration of claimed inhibitor of 10^{-7}M or more.

Claims 5 and 30 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Claims 5 and 30 are drawn to the modulation or regulation of cell proliferation or cell differentiation at concentration of claimed inhibitor of 1 nM or less. However, the specification discloses only the inhibition of cell proliferation (*vide supra*) and that Biliverdin has no effect on cell proliferation or survival at concentration less than 10^{-7}M (page 102). The prior art does not disclose that bilins inhibit cell proliferation at levels less than 1 μM (see Janes *et al.*, Figure 3, p. 2583). Hence, Applicant specifically discloses that bilins do not inhibit cell proliferation at concentrations of 10^{-8}M or less. The prior art does not suggest such a phenomenon. Hence, the degree of unpredictability is very high and one of ordinary skill in the art would not reasonably expect to inhibit cell proliferation wherein the concentration of the claimed inhibitor is 1 nM or less. Absent a further showing, the claims are not enabled.

Claims 1, 10-15, 18, 27-32 and 35-40 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for promoting cell differentiation in colon adenocarcinoma, lipocarcinoma, thyroid carcinoma and lymphoblast cells, does not reasonably provide enablement for promotion of differentiation in any other type of cell. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The claims are drawn to a method of modulating cell proliferation or differentiation or promoting cell proliferation with any type of cell with the claimed bilin. Applicant discloses the promotion of cellular differentiation with four specie of cancerous cells including colon adenocarcinoma, lipocarcinoma, thyroid carcinoma and lymphoblast cell lines by the addition of biliverdin to the cell culture. There is no disclosure in the specification of a similar effect on any other type of cells. A survey of the prior art did not yield any report of promotion of differentiation of any type of cell by treatment with a bilin such as bilirubin or biliverdin. The prior art describes widely different effects of linear bilins on differentiation. Sima *et al.*, disclose that continuous infusion of bilirubin suppresses immune response in mice by inhibiting the differentiation of immunocompetent cells (p. 1979, Discussion). Notter *et al.* disclose that bilirubin inhibits the differentiation of mitotically active cells to a greater degree than mature neurons (p. 676, first and second paragraphs). In contrast, Nakajima *et al.* report that neither bilirubin nor biliverdin has any effect on the differentiation of human leukemia

K562 cell line (chart on p. 723). In summary, the prior art discloses only the inhibition or neutral effect of the claimed bilins on cellular differentiation in cancerous and non-cancerous cell lines.

There appears to be no reliable method that predicts what types of cells will experience promotion of differentiation after contact with a claimed compound. The prior art discloses that linear bilins can have a neutral or inhibitory effect on cell differentiation. The specification discloses only the promotion of differentiation in four neoplastic cell lines by the claimed compounds. The specification does not teach how one of ordinary skill in the art could decide *a priori* when the claimed compounds will promote cell differentiation. The limited disclosure cannot be extrapolated by the skilled artisan to predict which types of cells will experience induction of cellular differentiation by a claimed. Given the great cellular diversity among even related species, it would require one of ordinary skill in the art undue experimentation to determine what types of cells would undergo an increase in differentiation when contacted with the claimed compounds according to the directions of the instant disclosure. Thus, claims 1, 10-15, 18, 27-32 and 35-40 are not commensurate in scope with the enabling disclosure.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –
(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 10, 14, 18 and 25 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Rhine *et al.* or Notter *et al.*

The claims are drawn to a method of modulating or regulating cell differentiation comprising treating a cell with a claimed compound based on formula I, wherein the cell is contacted *in vitro* and at least one occurrence of Y includes a carboxyl group and the bilin is bilirubin or biliverdin.

The broadest reasonable interpretation of modulating and regulating is that there is a promoting or inhibiting effect.

Rhine *et al.* teach the inhibition of differentiation of primary cultures of newborn rat cerebral cortical astrocytes by the administration of bilirubin (p.209, Fig.3).

Notter *et al.* disclose that bilirubin inhibits the differentiation of mitotically active cells to a greater degree than mature neurons (p. 676, first and second paragraphs).

Claims 1, 10, 15, 18 and 25 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Sima *et al.*

The claims are drawn to a method of modulating or regulating cell differentiation comprising treating a cell with a claimed compound based on formula I, wherein the cell is contact *in vivo* and at least one occurrence of Y includes a carboxyl group and the bilin is bilirubin or biliverdin.

The broadest reasonable interpretation of modulating and regulating is that there is a promoting or inhibiting effect.

Sima *et al.* disclose that continuous infusion of bilirubin suppresses immune response in live mice by inhibiting the differentiation of immunocompetent cells (p. 1979, discussion).

Claims 1-3, 6 and 22-24 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Janes *et al.* or Haga *et al.*

Janes *et al.* teach the inhibition of cell proliferation in human osteoblasts *in vitro* by unconjugated bilirubin at a concentration of 10-250 μ M (Figure 3, p. 2583).

Haga *et al.* disclose the inhibition of cell proliferation in human lymphocytes *in vitro* by bilirubin at a concentration of 30 μ M (p. 1471, right column).

Claims 27-28 and 31 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Janes *et al.* or Haga *et al.* in view of Phelan *et al.*

As discussed in the previous rejection *vide supra*, Janes *et al.* and Haga *et al.* teach the *in vitro* inhibition by bilins of cell proliferation in human osteoblasts and human lymphocytes, respectively. Neither Janes *et al.* nor Haga *et al.* expressly disclose mechanism of the binding of bilins by aryl hydrocarbon (AH) receptors. However, this property of bilins is deemed inherent in the disclosure of inhibition of proliferation by bilins. Phelan *et al.* support the inherency of this binding property. Phelan *et al.* teach that bilirubin and biliverdin can directly compete with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for binding sites on the AH receptor (see p. 159, right column). Since the cell lines disclosed by Janes *et al.* and Haga *et al.* possess AH receptors, it is inherent

Art Unit: 1651

that a bilin would bind to such a receptor during the process of the bilin inhibiting cellular proliferation. It is noted that the use of an extra reference to show an inherent characteristic of the thing taught by the primary reference is supported in the MPEP 2131. "To serve as an anticipation when the reference is silent about the asserted inherent characteristic, such gap in the reference may be filled with recourse to extrinsic evidence. Such evidence must make clear that the missing descriptive matter is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill." *Continental Can Co. USA v. Monsanto Co.*, 948 F.2d 1264, 1268, 20 USPQ2d 1746, 1749 (Fed. Cir. 1991).

Claims 27, 31, 32, 35, 39 and 40 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Rhine *et al.*, Notter *et al.* or Sima *et al.* in view of Phelan *et al.*

As previously discussed *vide supra*, the broadest reasonable interpretation of the words modulating and regulating includes inhibition. All three references disclose the inhibition of cellular differentiation by bilins. Rhine *et al.* and Notter *et al.* discuss *in vitro* experiments which cover claims 27, 31, 35 and 39. Sima *et al.* discloses the inhibition of differentiation in mice *in vivo*. This reference applies to claims 27, 32, 35 and 40.

None of the references expressly disclose mechanism of the binding of bilins by aryl hydrocarbon (AH) receptors. However, this property of bilins is deemed inherent in the disclosure of inhibition of proliferation by bilins. Phelan *et al.* support the inherency of this binding property. Phelan *et al.* teach that bilirubin and biliverdin can directly compete with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for binding sites on the AH

Art Unit: 1651

receptor (see p. 159, right column). Since the cells disclosed by said references possess AH receptors, it is inherent that a bilin would bind to such a receptor during the process of the bilin inhibiting cellular proliferation. It is noted that the use of an extra reference to show an inherent characteristic of the thing taught by the primary reference is supported in the MPEP 2131.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 7, 15 and 32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Janes *et al.* or Haga *et al.*

As discussed in the previous rejection *vide supra*, Janes *et al.* and Haga *et al.* teach the inhibition of cell proliferation *in vitro* in human osteoblasts and human lymphocytes, respectively. The binding of bilins to aryl hydrocarbon receptors during said inhibition is deemed to be an inherent property *vide supra* (applies to Claim 32).

Neither Janes *et al.* and Haga *et al.* disclose the inhibition of cell proliferation *in vivo*.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to inhibit cell proliferation *in vivo* by treating said cell with a bilin. On page p. 98 of the specification, Applicant states that, "The translation of *in vitro*

Art Unit: 1651

observations to *in vivo* conditions is greatly facilitated by a number of animal models that are currently in use to evaluate the efficacy of agents for the treatment of cancer.”

This statement is interpreted to mean that the employment of agents that are successful *in vitro* to *in vivo* usage is conventional because the use of established animal models in the art provides for a reasonable expectation of success for efficacy.


Allowable Subject Matter

The promotion of differentiation in colon adenocarcinoma, lipocarcinoma, thyroid carcinoma and lymphoblast cells by a claimed bilin appears to be neither anticipated nor obvious over the prior art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hanley whose telephone number is 703-305-1982. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached at 703-308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.


SEAN C. WITZ
PRIMARY EXAMINER

Application/Control Number: 10/008,356
Art Unit: 1651

Page 14